China's pioneer in the digital healthcare services market—Neusoft Xikang—lists on the Hong Kong Stock Exchange | Chenkun Family
Release date:
2023-09-28
On September 28, Dongrui Xikang, an investee fund of Tonghe Yucheng Investment Co., Ltd.—a sub-fund backed by the mother fund managed by Yuanhe Chencun—was listed on the Hong Kong Stock Exchange under the stock code: 9686.HK.
9 On the 28th of the month, "Neusoft Xikang," a portfolio company invested in by Tonghe Yucheng Investment Enterprise—a sub-fund backed by the mother fund managed by Yuanhe Chencun—was listed on the Hong Kong Stock Exchange under the stock code: 9686.HK.
Dongsoft Xikang Health Technology Co., Ltd., established in 2011, is a pioneer in China’s digital healthcare services market. The company is dedicated to leveraging information technology to drive transformative change in healthcare, empowering stakeholders across the industry and delivering tangible value. According to data from Frost & Sullivan, Dongsoft Xikang operates across four key business segments: Cloud Hospital Platform Services, Internet Healthcare Services, Health Management Services, and Smart Healthcare Products. Among these, Dongsoft Xikang primarily facilitates the delivery of internet-based healthcare services through its extensive network of Cloud Hospitals, offering solutions such as Internet Hospital Services, Remote Medical Services, Smart Home Services, and Internet-Driven Home Care Services. The company caters to diverse clients—including local governments, medical institutions, insurance providers, enterprises, and individuals—providing comprehensive, full-cycle digital healthcare solutions tailored to their unique needs.
Dongsoft Xikang will primarily use the funds raised this time to expand its cloud hospital platform, which serves as the entry point for cities, thereby strengthening the company’s medical network and growing its user base. Additionally, the capital will be allocated toward enriching the company’s product offerings across the entire industry value chain, enabling it to deliver more specialized and diversified healthcare services. A portion will also be invested in R&D for advanced technological infrastructure and enhanced data-processing capabilities. Furthermore, the funds will support potential M&A opportunities, as well as cover working capital needs and other general corporate purposes.
Suzhou:+86-0512-66969722
Beijing:+86-010-65000132
Scan QR code